Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...